Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Tax Provisions: 2012-2024

Historic Tax Provisions for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $46.8 million.

  • Amphastar Pharmaceuticals' Tax Provisions fell 42.61% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year decrease of 2.41%. This contributed to the annual value of $46.8 million for FY2024, which is 2.46% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Tax Provisions of $46.8 million as of FY2024, which was up 2.46% from $45.7 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Tax Provisions peaked at $46.8 million during FY2024, and registered a low of $3.5 million during FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Tax Provisions had a median value of $45.7 million in 2023 and averaged $44.0 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Tax Provisions slumped by 74.20% in 2020 and then spiked by 482.77% in 2021.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Tax Provisions stood at $3.5 million in 2020, then skyrocketed by 482.77% to $20.6 million in 2021, then surged by 90.77% to $39.4 million in 2022, then grew by 16.09% to $45.7 million in 2023, then increased by 2.46% to $46.8 million in 2024.